TB-500 and Injury Recovery: What Has Been Studied

What the research covers

No human study of TB-500 for injury recovery was found. Its key ingredient is a lab-made copy of a short piece of thymosin beta-4, a larger natural protein. The piece is 7 amino acids long.

The product and the full protein are not the same thing. Thymosin beta-4 has 43 amino acids. A 2024 lab paper said the effects of TB-500 itself have not been documented. In its cell tests, only one breakdown piece of TB-500 helped close a wound. The authors suggested that earlier wound results may come from that piece.

One rodent (rat) study tested TB-500 directly. After the Achilles tendon was cut and repaired, TB-500 was injected into the belly cavity. The dose was 60 micrograms per kg a day for 4 weeks. Tendons in this group were significantly stronger than in the control group. The authors described TB-500 as synthetic thymosin beta-4.

Other data come from the full protein. In a rodent (rat) study, thymosin beta-4 placed in a cut knee ligament improved healing at 4 weeks. In rodent (rat) skin wounds, it sped the regrowth of skin over the wound. In healthy people, it was given by IV at 42 to 1,260 mg for up to 14 days. It was well tolerated, but that study measured safety and drug levels, not healing.

Sources

1. Ruff D, Crockford D, Girardi G, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci (2010). PMID 20536472 doi:10.1111/j.1749-6632.2010.05474.x Human phase 1; full-length thymosin beta-4 (not TB-500) by IV, 42 to 1260 mg, single and 14 daily doses; well tolerated; no healing endpoint.
2. Guarnera G, DeRosa A, Camerini R The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci (2010). PMID 20536470 doi:10.1111/j.1749-6632.2010.05490.x Human phase 2, randomized, placebo-controlled, 73 people with venous leg ulcers; topical full-length thymosin beta-4 or placebo; describes it as a 43-amino-acid peptide.
3. Lee E, Padgett B Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med (2021). PMID 34324435 Human, uncontrolled retrospective chart review with phone survey, 16 people; 12 got knee injections of BPC-157 alone, 4 got BPC-157 plus thymosin-beta-4 (TB4), form not stated.
4. Bicer O, Adanir O, Guleryuz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg (2026). PMID 42542926 doi:10.52312/jdrs.2026.2951 Rodent (rat), repaired Achilles tendon; TB-500 60 micrograms per kg a day intraperitoneally for 4 weeks; significantly higher load to failure.
5. Xu B, Yang M, Li Z, et al. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat. Regul Pept (2013). PMID 23523891 doi:10.1016/j.regpep.2013.03.026 Rodent (rat), cut knee ligament; 1 microgram of full-length thymosin beta-4 in fibrin sealant; better tissue and strength at 4 weeks.
6. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol (1999). PMID 10469335 doi:10.1046/j.1523-1747.1999.00708.x Rodent (rat) full-thickness skin wounds; full-length thymosin beta-4 on the skin or intraperitoneally; faster skin regrowth at days 4 and 7.
7. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A (2012). PMID 23084823 doi:10.1016/j.chroma.2012.09.043 Identifies the key ingredient of TB-500 as acetylated LKKTETQ, the 17-23 segment of thymosin beta-4 (horse doping-control study).
8. Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci (2024). PMID 38382158 doi:10.1016/j.jchromb.2024.124033 Rodent (rat) and cell study; states TB-500 effects are undocumented; only the breakdown piece Ac-LKKTE showed wound-healing activity in cells.
9. Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal (2023). PMID 36482504 doi:10.1002/dta.3421 Analysis of products sold online as TB500; contents not consistently matching earlier descriptions.